Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)—Gene Rearrangements

6Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

The treatment failure rates of acute leukemia with rearrangements of the Mixed Lineage Leukemia (MLL) gene highlight the need for novel therapeutic approaches. Taking into consideration the limitations of the current therapies and the advantages of novel strategies for drug discovery, drug repurposing offers valuable opportunities to identify treatments and develop therapeutic approaches quickly and effectively for acute leukemia with MLL-rearrangements. These approaches are complimentary to de novo drug discovery and have taken advantage of increased knowledge of the mechanistic basis of MLL-fusion protein complex function as well as refined drug repurposing screens. Despite the vast number of different leukemia associated MLL-rearrangements, the existence of common core oncogenic pathways holds the promise that many such therapies will be broadly applicable to MLL-rearranged leukemia as a whole.

Cite

CITATION STYLE

APA

Tsakaneli, A., & Williams, O. (2021, September 14). Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)—Gene Rearrangements. Frontiers in Pharmacology. Frontiers Media S.A. https://doi.org/10.3389/fphar.2021.741413

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free